Skip to main content
ClinicalTrials.govrestricted

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surge

ClinicalTrials.gov study NCT02506153. IPD Sharing: Not stated. Countries: 3. Publications: 1.

ShareScore

36/100

Overall dataset sharing score

Score breakdown

These five areas show where the dataset supports — or may limit — practical reuse.

Stewardship
12
Harmonization
12
Access
4
Reuse readiness
0
Engagement
8

Topics

Dataset details

Repository
ClinicalTrials.gov
Published
February 11, 2026
License
IPD-UNDECIDED
DOI
clinicaltrials.gov/NCT02506153

Scored with release 0.9.0

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.